Video

In this webinar, broadcast on 20th July 2021, our expert panel discuss risk reduction and reversibility in haemorrhage with anticoagulation. To view the webinar you need to be a registered user of the BJC so please log in or register.

In this webinar, broadcast on 16th September 2020, our panel of experts discuss how we can start to optimally deliver key services in Scotland as the pandemic continues. To view the webinar you need to be a registered user of the BJC so please log in or register.

In this webinar, broadcast on 18th June 2020, our panel of experts discuss how we can start to optimally deliver key services as the pandemic eases. To view the webinar you need to be a registered user of the BJC so please log in or register.

In this webinar, broadcast on 2nd June 2020, our panel of experts discuss how the UK has adapted to new forms of service delivery during the COVID-19 pandemic and how this may help improve future patient care. To view the webinar you need to be a registered user of the BJC so please log in or register.

The DAPA-HF trial was hailed as a landmark study at the congress when the SGLT2 inhibitor, dapagliflozin, was shown to have an extraordinarily significant result versus placebo in reducing death and hospitilisation in patients with heart failure and reduced ejection fraction, both in those with and those without diabetes. The study is discussed by Professor David Hare (Professor of Medicine, University of Melbourne; Clinical Cardiologist, Austin Health, Victoria, Australia)

New guidance on diabetes, pre-diabetes and cardiovascular disease from the European Society of Cardiology (in collaboration with the European Association for the Study of Diabetes) was announced at the Congress. So what’s new? We find out from Professor Naveed Sattar (Professor of Metabolic Medicine, Institute of Cardiovascular and Medical Sciences, University of Glasgow)